Unusual vasovagal-type autonomic dysfunction secondary to immune checkpoint inhibitor therapy

被引：0

作者：

Danley, Kelsey ^{[1
]}

Fidler, Mary Jo ^{[2
]}

Sadaf, Aliyah ^{[1
]}

Okwuosa, Tochukwu M. ^{[3
]}

机构：

[1] Rush Univ, Med Ctr, Internal Med, Chicago, IL 60612 USA

[2] Rush Univ, Med Ctr, Oncol, Chicago, IL USA

[3] Rush Univ, Med Ctr, Dept Internal Med, Div Cardiol, Chicago, IL USA

来源：

BMJ CASE REPORTS | 2023年 / 16卷 / 02期

关键词：

Cancer; see Oncology; Cancer intervention; Cardiovascular system; ADVERSE EVENTS;

D O I：

10.1136/bcr-2022-251034

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We present the case of a patient with oral squamous cell carcinoma treated with the programmed death ligand inhibitor, pembrolizumab, an immune checkpoint inhibitor. She subsequently developed vasovagal-type autonomic dysfunction thought to be secondary to the pembrolizumab. The patient's vasovagal symptoms resolved with the initiation of oral glucocorticoids.

引用

页数：3

共 50 条

[31] Neurotoxicities associated with immune checkpoint inhibitor therapy
Sophie L. Duong
Frank J. Barbiero
Richard J. Nowak
Joachim M. Baehring
Journal of Neuro-Oncology, 2021, 152 : 265 - 277
[32] Predictive markers for immune checkpoint inhibitor therapy
Wiesweg, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 12 - 12
[33] Progress in Immune Checkpoint Inhibitor for Melanoma Therapy
Boutros, Celine
Herrscher, Hugo
Robert, Caroline
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (05) : 997 - 1010
[34] Neurotoxicities Associated with Immune Checkpoint Inhibitor Therapy
Duong, Sophie L.
Barbiero, Frank J.
Nowak, Richard J.
Baehring, Joachim M.
ANNALS OF NEUROLOGY, 2018, 84 : S138 - S138
[35] Interstitial nephritis in immune checkpoint inhibitor therapy
Manohar, Sandhya
Albright, Robert C., Jr.
KIDNEY INTERNATIONAL, 2019, 96 (01) : 252 - 252
[36] Immune Checkpoint Inhibitor Therapy in Breast Cancer
Santa-Maria, Cesar A.
Nanda, Rita
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (10): : 1259 - 1268
[37] Toxicity in the era of immune checkpoint inhibitor therapy
Keam, Synat
Turner, Naimah
Kugeratski, Fernanda G.
Rico, Rene
Colunga-Minutti, Jocelynn
Poojary, Rayansh
Alekseev, Sayan
Patel, Anisha B.
Li, Yuanteng Jeff
Sheshadri, Ajay
Loghin, Monica E.
Woodman, Karin
Aaroe, Ashley E.
Hamidi, Sarah
Iyer, Priyanka Chandrasekhar
Palaskas, Nicolas L.
Wang, Yinghong
Nurieva, Roza
FRONTIERS IN IMMUNOLOGY, 2024, 15
[38] An Unusual Presentation of Immune Checkpoint Inhibitor Hepatotoxicity With Cholestatic Transaminitis
Afzal, Soha
Davies, Alexandra
Vennikandam, Madhu
Lee-Allen, Jannel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S2337 - S2337
[39] CHECKPOINT CONFUSION, ASEPTIC ENCEPHALITIS AFTER IMMUNE CHECKPOINT INHIBITOR THERAPY
Roperia, Varun
CHEST, 2024, 166 (04) : 2342A - 2345A
[40] Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
Thapi, Sahityasri
Leiter, Amanda
Galsky, Matthew
Gallagher, Emily J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):

← 1 2 3 4 5 →